BEEM
BEAM GLOBAL (BEEM) Signs LOI to Buy European Drone Maker
Beam Global has signed a non-binding letter of intent to acquire an unnamed European drone and AI software company, aiming to build drones in its own US and EU plants.
News from SEC filings, FDA decisions and company releases, drafted with AI and checked by an editor before publication. How we work: redfiled.com/how-we-work/
BEEM
Beam Global has signed a non-binding letter of intent to acquire an unnamed European drone and AI software company, aiming to build drones in its own US and EU plants.
AZO
Fourth-quarter net sales rose 5.6% to $6.6 billion and net income climbed to $931.6 million, helped by tariff refunds and a LIFO benefit.
AZO
Fourth-quarter net sales rose 5.6% to $6.6 billion, with domestic same-store sales up 1.6% and gross margin widening 182 basis points.
CLDX
Both EMBARQ-CSU studies met their primary and all key secondary endpoints, with complete response rates above 42% at 12 weeks; BLA planned for 2027.
WDAY
Workday 10% owner David Duffield converted 94,089 shares into Class A stock and sold the same number on the open market at about $194 to $196 apiece.
CRWD
Seven CrowdStrike insiders filed Form 4s on the same day: CEO George Kurtz sold 20,000 shares and director Cary Davis sold 29,940, together about $12.2 million.
ANET
Andreas Bechtolsheim sold 300,000 Arista shares on Sept. 17 at prices between $193.61 and $204.31, leaving him with about 180.5 million shares.
GRAB
Chief Executive Anthony Tan and President and COO Alexander Hungate together bought about 10.65 million Grab shares near $2.89 on the same day.
LEN
Berkshire Hathaway bought about 2.74 million Lennar shares between September 17 and 21, lifting its Class A stake to 23.7 million shares.
HE
HEI monetized 30% of its 9.9% stake in American Savings Bank during the bank's IPO, cutting future capital needs for Maui wildfire settlement payments.
RIME
Algorhythm Holdings designated 100,000 Series B preferred shares with a $1,000 stated value, convertible into common stock only after shareholder approval.
PDSB
Corporate deck filed with the SEC shows a 71.4% six-month response rate for PDS0301 in liver-metastatic colorectal cancer and a new board seat for Patrick Soon-Shiong.